We are happy to announce that Einar Wanhainen joins Calissendorff Swarting as partner as per 1 March 2018. For more information about Einar and about the firm, please read the attached press release (in Swedish).
The Supreme Administrative Court (Sw: Högsta förvaltningsdomstolen) has granted the Church of Sweden (the Diocese of Linköping) leave to appeal in a dispute between the Diocese and the National Heritage Board concerning the legal concept of a “church site” (Sw: kyrkotomt) under the Culture Heritage Act of 1988.
Jan-Mikael Bexhed has been appointed chairman of a working group of seven prominent attorneys, who will lead the work to review and revise the Swedish Bar Association's Legal Certainty Program, which was launched nearly 30 years ago
Axel Calissendorff, founding partner, has been appointed special examiner (Sw. särskild granskningsman) by the board of directors of Eltel AB (publ) to investigate potential irregularities behind the considerable need for write-downs reported by the company 21 February 2016.
Calissendorff Swarting supports Swedish Orphan Biovitrum AB (publ) (Sobi) legal department with advice and lawyers for a longer period of time. Camilla Appelgren is primarily Calissendorff Swarting’s responsible partner. The assignment involves also Peter Nilsson, Martin Nyberg and other lawyers from the firm.
Sobi is an international specialty healthcare company dedicated to rare diseases with a mission to develop and deliver innovative therapies and services to improve the lives of patients. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.
Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of businesses in India, Sweden and the United States for 1.7 billion for the creation of a leading global CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical industry.
Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of 74 per cent of the shares in Nitin Lifesciences Limited, an Indian family owned Contract Manufacturing Organisation (CMO) that produces sterile injectables, for a purchase price of INR 6,713 million (SEK 824 million) on a cash and debt free basis.
Calissendorff Swarting represented Aprea AB, a subsidiary of Karolinska Development AB, in a SEK 437 million financing.